PMID- 24190963
OWN - NLM
STAT- MEDLINE
DCOM- 20140707
LR  - 20221207
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 24
IP  - 12
DP  - 2013 Dec
TI  - Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic 
      collecting duct carcinoma.
PG  - 2963-7
LID - 10.1093/annonc/mdt423 [doi]
AB  - BACKGROUND: Collecting duct carcinoma (CDC) is a rare and aggressive subtype of 
      kidney cancer that responds to platinum-based chemotherapy. Recent phase II 
      trials have established enhanced antitumor activity on combining bevacizumab with 
      chemotherapy in patients with metastatic urothelial carcinoma, a tumor that 
      shares many features with CDC. Our aim was to investigate whether combining 
      bevacizumab with platinum-based chemotherapy might not also show promise in 
      metastatic CDC (mCDC) patients. PATIENTS AND METHODS: Five previously untreated 
      patients diagnosed with mCDC received bevacizumab (15 mg/kg) in combination with 
      gemcitabine (1250 mg/m(2), D1-D8) and platinum salt (cisplatin 80 mg/m(2) or 
      carboplatin AUC 5 mg/ml/min) every 3 weeks for up to six cycles. This was 
      followed by bevacizumab maintenance therapy (15 mg/kg). RESULTS: All five 
      patients (median age, 62 years; range 45-66 years) had an Eastern Cooperative 
      Oncology Group PS of 0-1. They received the triple-drug combination for a median 
      of four cycles (range, 2-6) and bevacizumab maintenance therapy for a median of 
      three cycles (range, 0-17). There were three cases of partial response, one case 
      of stable disease (20 months) and one case of complete remission after surgery of 
      the only metastatic site. Median progression-free survival (PFS) was 15.1 months 
      [95% confidence interval (CI) 5.6-20.4]. Median overall survival (OS) was 27.8 
      months (95% CI 12.4-unreached). Grades 3 or 4 adverse events were pulmonary 
      embolism (n = 2), neutropenia (n = 2), thrombopenia (n = 1), asthenia (n = 1) and 
      hypertension (n = 1). CONCLUSIONS: The addition of bevacizumab to platinum-based 
      chemotherapy resulted in a longer PFS and longer OS than recorded in an earlier 
      clinical trial of platinum-based chemotherapy alone. The triple combination was 
      manageable. The French Collaborative Group (Groupe d'Etudes des Tumeurs 
      Uro-Genitales) is planning a prospective multicenter phase II clinical trial of 
      the triple combination in mCDC patients. CLINICAL TRIAL: BEVABEL/MO28644 
      (EudraCT: 2013-001179-19).
FAU - Pecuchet, N
AU  - Pecuchet N
AD  - Department of Medical Oncology, Hopital Europeen Georges Pompidou, Paris.
FAU - Bigot, F
AU  - Bigot F
FAU - Gachet, J
AU  - Gachet J
FAU - Massard, C
AU  - Massard C
FAU - Albiges, L
AU  - Albiges L
FAU - Teghom, C
AU  - Teghom C
FAU - Allory, Y
AU  - Allory Y
FAU - Mejean, A
AU  - Mejean A
FAU - Escudier, B
AU  - Escudier B
FAU - Oudard, S
AU  - Oudard S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131104
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - BG3F62OND5 (Carboplatin)
RN  - Q20Q21Q62J (Cisplatin)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bevacizumab
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Renal Cell/*drug therapy/mortality/secondary
MH  - Cisplatin/administration & dosage
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Disease-Free Survival
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Kidney Neoplasms/*drug therapy/mortality/pathology
MH  - Maintenance Chemotherapy
MH  - Middle Aged
MH  - Treatment Outcome
MH  - Gemcitabine
OTO - NOTNLM
OT  - bevacizumab
OT  - carboplatin
OT  - cisplatin
OT  - collecting duct carcinoma
OT  - gemcitabine
EDAT- 2013/11/06 06:00
MHDA- 2014/07/08 06:00
CRDT- 2013/11/06 06:00
PHST- 2013/11/06 06:00 [entrez]
PHST- 2013/11/06 06:00 [pubmed]
PHST- 2014/07/08 06:00 [medline]
AID - S0923-7534(19)36751-1 [pii]
AID - 10.1093/annonc/mdt423 [doi]
PST - ppublish
SO  - Ann Oncol. 2013 Dec;24(12):2963-7. doi: 10.1093/annonc/mdt423. Epub 2013 Nov 4.